Dr Ariele H Foster, PT, DPT, E-RYT500 | |
3000 Connecticut Ave Nw Apt 434, Washington, DC 20008 | |
(000) 000-0000 | |
Not Available |
Full Name | Dr Ariele H Foster |
---|---|
Gender | Female |
Speciality | Physical Therapist |
Location | 3000 Connecticut Ave Nw Apt 434, Washington, District Of Columbia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1255613501 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208100000X | Physical Medicine & Rehabilitation | PT871268 (District Of Columbia) | Secondary |
225100000X | Physical Therapist | PT871268 (District Of Columbia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Ariele H Foster, PT, DPT, E-RYT500 3000 Connecticut Ave Nw Suite 434, Washington, DC 20008 Ph: (000) 000-0000 | Dr Ariele H Foster, PT, DPT, E-RYT500 3000 Connecticut Ave Nw Apt 434, Washington, DC 20008 Ph: (000) 000-0000 |
News Archive
An international, multidisciplinary research team from more than 50 institutions, led by geneticist and psychiatrist Gholson Lyon, MD, PhD, of the New York State Office for People With Developmental Disabilities' Institute for Basic Research in Developmental Disabilities, today announced publication of findings from its study of the rare disease TAF1 syndrome.
The American Journal of Industrial Medicine recently published a study showing that World Trade Center (WTC) responders suffer from asthma at more than twice the rate of the general U.S. population as a result of their exposure to the toxic dust from the collapse of the WTC towers in 2001. Preliminary study results were previously presented in CHEST in 2009.
The U.S. Preventive Services Task Force finds scant evidence that the PSA blood test saves lives and instead says unneeded treatment leads to serious problems, including impotence and incontinence.
Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.
McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is recalling one product lot of TYLENOL 8 Hour Extended Release Caplets 150 count bottles distributed in the United States.
› Verified 6 days ago